huPBMC Humanized Model

Inquiry

The huPBMC humanized model is a pivotal preclinical research tool. It involves the engraftment of human PBMCs into severely immunodeficient mice, leading to the reconstitution of a functional, T-cell-dominated human immune system. This model enables the evaluation of human immune cell responses to tumors or therapeutic agents in a live environment. Leveraging this established technology, Alfa Cytology's huPBMC humanized mouse models are the ideal tool for short-term, highly efficient immunotherapy screening. Through our optimized protocols, we achieve rapid and stable immune reconstitution, delivering powerful and reliable in vivo efficacy data within a compact timeline to accelerate your journey from candidate screening to mechanism verification.

Introduction to huPBMC Humanized Model

Renowned for its short cycle and potent effects, the huPBMC humanized model is the "gold standard" in preclinical evaluation of oncology immunotherapies. It efficiently reconstructs functional human T cells and enables their infiltration into tumor tissue, closely mimicking human immune responses. This model demonstrates unparalleled sensitivity in evaluating T cell-mediated therapies like CAR-T and immune checkpoint inhibitors. Through stringent donor screening and quality control, we significantly enhance model success rate and stability, extending the experimental window to over 3 weeks to meet most efficacy study requirements.

Fig.1 Schematic diagram of the huPBMC-NCG model establishment process.

Applications of huPBMC Humanized Model

Both preclinical studies and published literature have validated the huPBMC humanized model as a robust platform for evaluating the efficacy of diverse cancer immunotherapies. As illustrated in the table below, this model has been successfully applied to the study of various solid tumors and hematological malignancies, including pancreatic cancer, ovarian cancer, lymphoma, and renal cell carcinoma. It effectively supports the assessment of core therapeutic strategies such as CAR-T cell therapy and immune checkpoint inhibitors. These cases underscore the critical value of the huPBMC model in mimicking human immune responses and predicting clinical efficacy.

Cancers	Human Immune Cells	Mouse Strains	Immunotherapeutic Methods
Pancreatic Cancer	PBMC	NSG	CAR-T
Ovarian Cancer	PBMC	\	CAR-T
Lymphoma	PBMC	NSG	Immune Checkpoint Inhibitor (anti-CTLA-4)
Renal Cell Carcinoma	PBMC	NSG	CAR-T / PD-L1
Mesothelioma	PBMC	NOD	CAR-T / PD-1
Colon/Gastric Cancer	PBMC	NSG	hCD137 / PD-1
Non-small Cell Lung Cancer	PBMC	NSI	Immune Checkpoint Inhibitor (anti-D-1/PD-L1 antibody)

Our Services

Unlock the full potential of your immuno-oncology research with the Hu-Immune™ platform. Alfa Cytology provides a rapid, stable, and reliable huPBMC humanized mouse model generation service. Our proprietary Hu-Immune™ platform is designed to deliver robust human immune system reconstitution, accelerating your preclinical immunotherapy evaluation with highly predictive in vivo data.

Our huPBMC Humanized Models

huPBMC Models	Key Features	Main Applications
huPBMC-T Mice	More stable T-cell reconstitution. Optimized for high-efficiency, stable T-cell reconstitution, making it the gold standard model for T cell-related immunotherapy research.	CAR-T/TCR-T cell therapy evaluation, immune checkpoint inhibitor (e.g., PD-1/PD-L1) efficacy, bispecific antibody assessment.
huPBMC-NK/B Mice	Clinical-level NK or B cell reconstitution. Achieves NK and B cell reconstitution close to human physiological levels, ideal for evaluating NK/B cell-related functions.	NK cell therapy, antibody-dependent cell-mediated cytotoxicity (ADCC) studies, B cell-targeting drug evaluation.
huPBMC-Mono Mice	Macrophage and DC reconstitution for cancer vaccines. Focuses on the reconstitution and function of monocytes/macrophages/dendritic cells for studying the role of myeloid cells in the tumor microenvironment.	Macrophage-targeting drugs (e.g., CD47 antibodies), cancer vaccine evaluation, tumor microenvironment research.
huPBMC-MHC KO Mice	*Longer dosing window for in vivo* immune therapy efficacy**. Significantly delays graft-versus-host disease (GvHD) onset through innovative technology, effectively extending the treatment window for long-term dosing studies.	Long-term efficacy studies, combination therapy evaluation, exploratory research requiring wider observation windows.

Workflow for huPBMC Humanized Model Studies

Alfa Cytology has established a standardized workflow for huPBMC model studies, ensuring exceptional reproducibility and data reliability at every stage, from model generation to final data delivery.

Donor Screening & PBMC Preparation

High-quality human PBMCs are isolated from pre-screened, healthy donors to guarantee reliable sources and stable cell viability, laying the foundation for successful model establishment.

Immune System Humanization & Reconstitution

PBMCs are engrafted into immunodeficient mice. Through precise process management and regular monitoring, stable and efficient, T-cell-dominated immune reconstitution is achieved.

Tumor Model Establishment

Following successful immune reconstitution, specific human tumor cell lines or patient-derived tumor tissues are implanted to establish stable tumor-bearing models for efficacy evaluation.

Drug Treatment & Efficacy Evaluation

Within a defined therapeutic window, test articles (such as immune checkpoint inhibitors, cell therapies, or bispecific antibodies) are administered, and their antitumor activity and immunomodulatory effects are systematically assessed.

Endpoint Analysis & Data Reporting

A comprehensive analysis is conducted, including evaluation of tumor growth inhibition, immune cell infiltration, cytokine secretion, and potential toxicity, culminating in a detailed and robust study report.

Case Study

Case 1: Evaluating CD3 Bispecific Antibody Efficacy in a huPBMC Humanized Model

Overview

Evaluate antitumor activity of a CD3 bispecific antibody (BsAb) and confirm robust human immune reconstitution in a Hu-Immune™ huPBMC humanized NCG model.

Study Information

Humanized Model: Hu-Immune™ huPBMC on NCG strain
Tumor Model: Hs 695T
Treatment: CD3 Bispecific Antibody (BsAb)

Results

Enhanced Model Stability: Achieved a modeling success rate >70% higher than conventional PBMC models.
Potent Efficacy: CD3 BsAb treatment resulted in significant tumor growth inhibition.

CD3 BsAb efficacy study in huPBMC Humanized Model.

Fig.2 CD3 BsAb efficacy study in huPBMC Humanized Model.

Why Choose Our huPBMC Platform?

Multi-immune cell reconstitution

Reconstitutes T, B, NK, DC and monocytes etc.

Highly versatile, simple solution

Compatible with CDX and PDX models, encompasses various human tumor endpoints and immune targets.

Stable Experimental system

The reconstruction success rate reaches 90% (compared to 35-50% for the conventional PBMC model)

Low Experimental Cost

The cost is reduced by 50% compared to the CD34⁺ model, while providing a more complete reconstitution.

Ready to obtain fast and reliable in vivo immune efficacy data? Alfa Cytology's huPBMC humanized models are designed for efficient and precise researchers like you. Contact our scientific team today for a customized study proposal.

For research use only.

Hu-Immune^TM Platform

Online Inquiry

Name *

Email *

Phone

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.